中国肿瘤临床
中國腫瘤臨床
중국종류림상
CHINESE JOURNAL OF CLINICAL ONCOLOGY
2013年
21期
1318-1323
,共6页
养正消积胶囊%恶性肿瘤%癌前病变%Meta分析%安全性
養正消積膠囊%噁性腫瘤%癌前病變%Meta分析%安全性
양정소적효낭%악성종류%암전병변%Meta분석%안전성
Yangzhengxiaoji capsule%cancer%precancerosis%meta-analysis%safety
目的：评价养正消积胶囊治疗恶性肿瘤及癌前病变的安全性。方法：通过计算机检索中英文数据库，包括CNKI （中国期刊全文专题数据库）、万方电子期刊、维普全文电子期刊（中国科技期刊数据库），以及PubMed、Science Direct Online、MEDLINE@EBSCO，纳入养正消积胶囊治疗恶性肿瘤及癌前病变的临床试验研究。利用Cochrane图书馆手册5.0推荐方法对纳入研究进行质量评价、数据提取，最后采用Revman 5.0软件进行Meta分析。结果：本研究共纳入文献19篇，采用养正消积胶囊治疗患者总计2125例，Meta分析结果显示，养正消积胶囊辅助化/放疗组的骨髓抑制、白细胞下降、血小板下降、消化道反应、恶心/呕吐、肝脏毒性不良反应发生率显著低于单纯化/放疗组（P<0.05），肾脏毒性、心脏毒性以及神经毒性发生率不高于单纯化疗组（P>0.05）。结论：养正消积胶囊在治疗恶性肿瘤及癌前病变的应用中具有良好的安全性。
目的：評價養正消積膠囊治療噁性腫瘤及癌前病變的安全性。方法：通過計算機檢索中英文數據庫，包括CNKI （中國期刊全文專題數據庫）、萬方電子期刊、維普全文電子期刊（中國科技期刊數據庫），以及PubMed、Science Direct Online、MEDLINE@EBSCO，納入養正消積膠囊治療噁性腫瘤及癌前病變的臨床試驗研究。利用Cochrane圖書館手冊5.0推薦方法對納入研究進行質量評價、數據提取，最後採用Revman 5.0軟件進行Meta分析。結果：本研究共納入文獻19篇，採用養正消積膠囊治療患者總計2125例，Meta分析結果顯示，養正消積膠囊輔助化/放療組的骨髓抑製、白細胞下降、血小闆下降、消化道反應、噁心/嘔吐、肝髒毒性不良反應髮生率顯著低于單純化/放療組（P<0.05），腎髒毒性、心髒毒性以及神經毒性髮生率不高于單純化療組（P>0.05）。結論：養正消積膠囊在治療噁性腫瘤及癌前病變的應用中具有良好的安全性。
목적：평개양정소적효낭치료악성종류급암전병변적안전성。방법：통과계산궤검색중영문수거고，포괄CNKI （중국기간전문전제수거고）、만방전자기간、유보전문전자기간（중국과기기간수거고），이급PubMed、Science Direct Online、MEDLINE@EBSCO，납입양정소적효낭치료악성종류급암전병변적림상시험연구。이용Cochrane도서관수책5.0추천방법대납입연구진행질량평개、수거제취，최후채용Revman 5.0연건진행Meta분석。결과：본연구공납입문헌19편，채용양정소적효낭치료환자총계2125례，Meta분석결과현시，양정소적효낭보조화/방료조적골수억제、백세포하강、혈소판하강、소화도반응、악심/구토、간장독성불량반응발생솔현저저우단순화/방료조（P<0.05），신장독성、심장독성이급신경독성발생솔불고우단순화료조（P>0.05）。결론：양정소적효낭재치료악성종류급암전병변적응용중구유량호적안전성。
Objective:To evaluate the safety of Yangzhengxiaoji capsules for the treatment of cancer and precancerosis. Methods:Clinical trials and studies were collected by searching Chinese and English databases, including CNKI, WANFANG database, VIP information database, Pubmed, ScinenceDirect Online, and MEDLINE@EBSCO. The clinical data of Yangzhengxiaoji capsule for the treatment of cancer and pre-cancerosis were included. The quality of the included studies was then evaluated. Related data were extracted with reference to Cochrane Handbook 5.0. Afterward, meta-analysis was conducted using Revman 5.0 software. Results:A total of 19 studies focusing on 2 125 patients receiving Yangzhengxiaoji capsules were included and investigated in this meta-analysis. Results showed that the adverse reaction rates of myelosuppression, WBC and platelet decrease, gastrointestinal reaction, nausea/vomiting, and hepatotoxicity were sig-nificantly lower in the trial groups with Yangzhengxiaoji capsule-assisted chemotherapy/radiotherapy than in the control groups with chemotherapy/radiotherapy only (P<0.05). The adverse reaction rates of nephrotoxicity, cardiotoxicity, and neurotoxicity were not statistically different between the trial groups and the control groups (P>0.05). Conclusion:Yangzhengxiaoji capsule could be safely administered to treat cancer and precancerosis.
